Cargando…
Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice
BACKGROUND & AIMS: Oxidative stress is recognized as a major driver of non-alcoholic steatohepatitis (NASH) progression. The transcription factor NRF2 and its negative regulator KEAP1 are master regulators of redox, metabolic and protein homeostasis, as well as detoxification, and thus appear to...
Autores principales: | Seedorf, Klaus, Weber, Csaba, Vinson, Cedric, Berger, Sylvie, Vuillard, Laurent-Michel, Kiss, Arpad, Creusot, Stephanie, Broux, Olivier, Geant, Anne, Ilic, Catherine, Lemaitre, Karine, Richard, Johann, Hammoutene, Adel, Mahieux, Julien, Martiny, Virginie, Durand, Didier, Melchiore, Fabien, Nyerges, Miklos, Paradis, Valerie, Provost, Nicolas, Duvivier, Valérie, Delerive, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971056/ https://www.ncbi.nlm.nih.gov/pubmed/36866391 http://dx.doi.org/10.1016/j.jhepr.2022.100651 |
Ejemplares similares
-
Characterization and Pharmacological Validation of a Preclinical Model of NASH in Göttingen Minipigs
por: Duvivier, Valérie, et al.
Publicado: (2022) -
Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosis but not NASH progression
por: Sansilvestri Morel, Patricia, et al.
Publicado: (2022) -
A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease
por: Hammoutene, Adel, et al.
Publicado: (2023) -
Current therapies and new developments in NASH
por: Dufour, Jean-François, et al.
Publicado: (2022) -
Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma
por: Udoh, Utibe-Abasi S., et al.
Publicado: (2022)